ADHD medication follow-up visits in New Jersey

Once ADHD medication is working, care settles into a routine of follow-up visits and new prescriptions. New Jersey regulates that routine more closely than most states. Since July 8, 2026, state law has set a minimum schedule of visits for adults who take a Schedule II stimulant prescribed through telehealth. Separate state rules cap how much stimulant can be prescribed at once. This page explains both, what a follow-up visit usually covers, and the questions to ask so you never run short.

The New Jersey schedule for stimulant patients

P.L.2026, c.40 amended New Jersey's telehealth statute (N.J.S.A. 45:1-62) and took effect when it was approved on July 8, 2026. For an adult patient prescribed a Schedule II stimulant through telemedicine or telehealth, the law says:

Three points are easy to miss.

• Video, not phone. The statute authorizes Schedule II prescribing through telehealth only when the clinician uses real-time audio and video. A phone call alone does not meet that condition.
• The three-month contact is a floor. The law sets the minimum. It does not stop a prescriber from seeing you more often, and early in treatment most will.
• It depends on where you are. The rule applies when you are located in New Jersey for the visit, because New Jersey's statute governs care provided to patients in the state. If you live in New Jersey but take visits while physically in New York, see living in New Jersey, getting ADHD care in New York.

A short history explains why older pages online disagree. Before c.40, the statute said Schedule II prescribing through telehealth required an initial in-person examination and an in-person visit every three months. The 2026 law kept a quarterly contact but allowed it by video, and replaced the quarterly in-person visit with a yearly one. The full timeline is in telehealth ADHD prescriptions in New Jersey in 2026.

Which medicines the schedule covers

The rule covers stimulants that are Schedule II controlled substances, such as lisdexamfetamine, whose label lists it as Schedule II. It does not by its terms reach medicines that are not controlled. The atomoxetine label, for example, states that it is not a controlled substance. Visit frequency for a non-controlled medicine is left to the clinician's judgment and the standard of care.

How prescriptions fit between visits

A visit and a prescription are separate events. The rules on prescriptions shape how often you need to be in touch with the practice even when no visit is due.

• No refills. Federal regulation (21 CFR 1306.12) says a Schedule II prescription may not be refilled. Every fill needs a new prescription.
• A 30-day limit per prescription. New Jersey's Board of Medical Examiners rule (N.J.A.C. 13:35-7.6) limits a Schedule II prescription to a 30-day supply.
• Up to 90 days through several dated prescriptions. The same rule lets a physician issue multiple prescriptions covering up to a 90-day supply in total. Each one after the first must state the earliest date a pharmacy may fill it, and the physician must decide that doing so does not create an undue risk of diversion or abuse. Federal regulation allows the same arrangement.

So a stable patient might have a video contact every three months and leave each one with three dated prescriptions. Another prescriber might prefer monthly prescriptions and closer visits. Both fit within the rules. Whether a 90-day arrangement is offered is the prescriber's decision, and an insurer or pharmacy may limit quantities. The supply rules are covered in full in New Jersey's ADHD medication rules.

What a follow-up visit usually covers

No New Jersey rule lists the contents of a follow-up. The telehealth statute requires telehealth care to meet the same standard of care as in-person care, and it says a clinician must direct a patient to in-person care when telehealth would fall short of that standard. In practice, the content comes from the drug labels and FDA guidance.

• Benefit. Whether the medicine is helping with the things that brought you in: work, school, home, driving, relationships. Bring specific examples.
• Side effects. The lisdexamfetamine label lists decreased appetite, insomnia, dry mouth, anxiety and irritability among the most common adverse reactions in adults. Report any of them, and when in the day they happen.
• Blood pressure and pulse. Stimulant labels tell prescribers to monitor blood pressure and pulse. If visits are by video, you may be asked to take readings at home and share them.
• Mood and other conditions. Labels tell prescribers to screen for risk of a manic episode before starting a stimulant. Changes in mood, anxiety or sleep belong in every follow-up.
• Safe use. FDA says prescribers should assess the risk of misuse, abuse and addiction before prescribing, and regularly assess and monitor for nonmedical use throughout treatment. Expect questions about how you take the medicine, storage, and whether any has been lost.
• Changes in your health. New medicines, a new diagnosis, pregnancy or plans for it, or substance use.
• The plan. Whether to keep the same regimen, adjust it, or try something else, and when the next contact is due.

New Jersey's controlled-substance rule also requires a practitioner starting a controlled substance to take a history, examine the patient, make a reasonable effort to get records, check the state Prescription Monitoring Program and write a treatment plan. Follow-ups are where that plan is checked against how you are actually doing. For the first months on a medicine, see starting ADHD medication: the first three months.

What the guidelines say about frequency

As of October 2026, the United States has no published clinical practice guideline specific to adult ADHD. The American Professional Society of ADHD and Related Disorders announced in August 2026 that its guideline had entered final review, with publication anticipated in the fall. Until it appears, no American guideline sets a follow-up interval for adults, and New Jersey's statutory schedule is the only fixed number that applies.

Federal rules and 2027

Two layers of law apply to video prescribing. New Jersey's c.40 is one. The other is federal. Through December 31, 2026, federal telemedicine flexibilities let DEA-registered practitioners prescribe controlled substances by telemedicine without a prior in-person evaluation. Under the underlying federal law, once a practitioner has conducted at least one in-person medical evaluation of a patient, the federal limits on remote prescribing no longer apply to that relationship. New Jersey's required in-person visits will often satisfy that condition as well. No final federal rule for 2027 had been published as of October 19, 2026.

Insurance and follow-up visits

P.L.2026, c.29 extended New Jersey's telehealth payment parity through December 31, 2027. Until then, state-regulated health benefits plans must pay for covered telehealth services at the same provider rate as in-person services, with exceptions in the law. Coverage questions are covered in does insurance cover adult ADHD in New Jersey. For current fees and how insurance works with this practice, call the office.

Questions to ask your prescriber

1. How often will you want to see me in the first three months, and after that?
2. When is my in-person visit due, and where would it take place?
3. Do you issue prescriptions between visits, and how far ahead should I ask?
4. Do you write dated prescriptions covering more than 30 days for stable patients?
5. Should I check my blood pressure at home before video visits?
6. What happens if I am traveling outside New Jersey when a visit is due?

At this practice, follow-up visits are held by secure video, and the office will explain how visits are arranged for patients located in New Jersey. How ongoing care works is described under adult ADHD treatment and appointments and telehealth.